# Drugs Detected in Suspected Pediatric Exposures: A 5-Year Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pediatric-cannabis-exposure-detection-5-year-review/ > **Published:** 2026-03-26T11:08:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:48-04:00 > **Clinical Summary:** Explore pediatric cannabis exposure detection in suspected drug cases over five years, highlighting comprehensive toxicology findings and clinical implications. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic PediatricToxicologyThcSafety[Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Journal Clinical toxicology (Philadelphia, Pa.) Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This 5-year toxicology surveillance study provides critical baseline data on [pediatric cannabis](https://cedclinic.com/cannabis-for-childrens-behavior/) exposures as legalization expands access to higher-potency products. Understanding detection patterns helps clinicians anticipate presentations and guides appropriate laboratory workup in suspected pediatric ingestions. Clinical Summary Researchers analyzed over 6,000 urine specimens from pediatric patients with suspected toxic exposures across two hospitals over five years, comparing immunoassay screens with comprehensive gas chromatography-mass spectrometry analysis. Cannabinoids ranked among the most frequently detected substances via immunoassay (33% positive rate) and carboxy-THC was identified as one of the most common compounds detected by comprehensive analysis (85% detection rate). The study demonstrates the clinical reality that cannabis metabolites are commonly encountered in pediatric toxicology workups, reflecting broader societal access patterns. Dr. Caplan’s Take “This data confirms what we’re seeing clinically—pediatric cannabis exposures are increasingly common and warrant systematic detection protocols. The high detection rates underscore the need for comprehensive toxicology screening when cannabis ingestion is suspected, as immunoassays alone may miss important co-exposures.” Clinical Perspective 🧠 Clinicians should maintain high suspicion for cannabis exposure in pediatric patients presenting with altered mental status or unexplained symptoms, particularly in states with legal adult use. Parents should be counseled on secure storage of all cannabis products, and [healthcare systems](https://cedclinic.com/australian-medical-cannabis-program-challenges/) should ensure toxicology protocols can detect both traditional and emerging [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/). 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Drugs%20detected%20in%20suspected%20pediatric%20exposures%3A%20a%205-year%20review.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41631875/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41631875/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Drugs%20detected%20in%20suspected%20pediatric%20exposures%3A%20a%205-year%20review.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41631875/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41631875/](https://pubmed.ncbi.nlm.nih.gov/41631875/) Table of Contents - [FAQ](#FAQ)[What percentage of pediatric patients with suspected toxic exposures test positive for cannabis?](#What_percentage_of_pediatric_patients_with_suspected_toxic_exposures_test_positive_for_cannabis) - [How reliable are standard urine immunoassay screens compared to comprehensive testing in pediatric toxicology cases?](#How_reliable_are_standard_urine_immunoassay_screens_compared_to_comprehensive_testing_in_pediatric_toxicology_cases) - [What are the most commonly detected substances in pediatric patients presenting with suspected ingestions?](#What_are_the_most_commonly_detected_substances_in_pediatric_patients_presenting_with_suspected_ingestions) - [Should comprehensive toxicology testing be considered for all pediatric patients with suspected drug exposures?](#Should_comprehensive_toxicology_testing_be_considered_for_all_pediatric_patients_with_suspected_drug_exposures) - [How do changes in cannabis legalization laws affect pediatric exposure patterns?](#How_do_changes_in_cannabis_legalization_laws_affect_pediatric_exposure_patterns) - [Related](#Related) ## FAQ #### What percentage of pediatric patients with suspected toxic exposures test positive for cannabis? Cannabinoids were among the most frequently detected substances in immunoassay screens, which were positive in 33% of all specimens tested. Specifically, carboxy-tetrahydrocannabinol (THC metabolite) was identified as one of the most commonly detected compounds using comprehensive gas chromatography-mass spectrometry analysis. #### How reliable are standard urine immunoassay screens compared to comprehensive testing in pediatric toxicology cases? Standard immunoassay screens detected drugs in only 33% of specimens, while comprehensive gas chromatography-mass spectrometry detected substances in 85% of cases. This significant difference suggests that relying solely on immunoassay screening may miss many clinically relevant exposures in pediatric patients. #### What are the most commonly detected substances in pediatric patients presenting with suspected ingestions? The most frequently detected compounds included caffeine, nicotine, carboxy-tetrahydrocannabinol, antihistamines, antipyretics, antidepressants, antipsychotics, and anticonvulsants. Cannabis metabolites ranked as the third most common substance detected, highlighting the prevalence of cannabis exposure in this pediatric population. #### Should comprehensive toxicology testing be considered for all pediatric patients with suspected drug exposures? Given that comprehensive testing detected substances in 85% of cases compared to 33% with standard immunoassays, broader testing may be clinically warranted. The high detection rate with advanced methods suggests that standard screening may inadequately assess the scope of pediatric toxic exposures. #### How do changes in cannabis legalization laws affect pediatric exposure patterns? The study notes that changes in drug laws necessitate updated data on common exposures, with cannabis metabolites being among the top detected substances. This suggests that evolving cannabis accessibility may be contributing to increased pediatric exposures, requiring enhanced vigilance and appropriate testing protocols. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Drugs detected in suspected pediatric exposures: a 5-year review.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41631875/”, “about”: “clinical toxicology philadelphia pa clinical study”, “isPartOf”: “Clinical toxicology (Philadelphia, Pa.)”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Pediatric Cannabis Exposure Emergency Department Detection Study](https://cedclinic.com/pediatric-cannabis-exposure-emergency-department-detection-study/) A detailed study on emergency department detection of [pediatric cannabis](https://cedclinic.com/cannabis-for-childrens-behavior/) exposures, providing clinical insights and detection challenges. [Read More](https://cedclinic.com/pediatric-cannabis-exposure-emergency-department-detection-study/) [Cannabinoid Therapies in Less-Common Disorders](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) Explore [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) and formulation strategies for cannabinoid therapies in less-common disorders, relevant to pediatric toxicology contexts. [Explore Now](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) [Unregulated Substance Abuse and Systemic Inflammation Markers](https://cedclinic.com/inflammatory-biomarkers-unregulated-substance-use-review/) A review of systemic inflammation markers linked to unregulated substance abuse, offering context for pediatric exposure risks. [Learn More](https://cedclinic.com/inflammatory-biomarkers-unregulated-substance-use-review/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).